Immunic misses primary endpoint in Phase 2 ulcerative colitis tria;

 Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids –

– In UC Population Without Concurrent Steroid Use, Pooled Vidofludimus Calcium Data Suggest Activity in Clinical Remission Over Placebo; Counterbalanced by Interference Observed in the UC Population with Concurrent Steroid Use –

– Company Does Not Plan Further Development Activities in Ulcerative Colitis Without a Partner –

– Focus to Remain on Ongoing Phase 3 Development of Vidofludimus Calcium in Multiple Sclerosis, and Ongoing IMU-935 and IMU-856 Programs with Clinical Data for Both Expected in 2022 –

– $93.1 Million in Cash and Cash Equivalents as of May 31, 2022 Expected to Fund Immunic
Into the Fourth Quarter of 2023 –

– Conference Call and Webcast, Including a Corporate Update, to be Held today,
June 2, 2022 at 8:00 am ET –

Immunic will host a webcast today at 8:00 am ET. To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_XgdotnImTHKxQiLFa958mA or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations.

https://finance.yahoo.com/news/immunic-inc-reports-top-line-103000663.html